313 related articles for article (PubMed ID: 35033015)
1. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report.
Rieker L; Hofer J; Petzold G; Ellenrieder V; Amanzada A
BMC Gastroenterol; 2022 Jan; 22(1):22. PubMed ID: 35033015
[TBL] [Abstract][Full Text] [Related]
2. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.
Hoffmann P; Wehling C; Krisam J; Pfeiffenberger J; Belling N; Gauss A
World J Gastroenterol; 2019 Apr; 25(13):1603-1617. PubMed ID: 30983820
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.
Alhalabi M; Eddin KA; Ali F; Abbas A
Medicine (Baltimore); 2022 Jan; 101(4):e28722. PubMed ID: 35089243
[TBL] [Abstract][Full Text] [Related]
4. Recovery from COVID-19 Pneumonia in a Patient with Acute Severe Colitis.
Garcia KS; Moutinho BD; de Azevedo MFC; Queiroz NSF; Milani LR; Sanches LN; Barros LL; Oba J; Carlos AS; Damião AOMC; Sipahi AM
Inflamm Intest Dis; 2020 Jun; 5(2):93-97. PubMed ID: 32984404
[TBL] [Abstract][Full Text] [Related]
5. Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature.
Rosen MH; Axelrad J; Hudesman D; Rubin DT; Chang S
Inflamm Bowel Dis; 2020 Jun; 26(7):971-973. PubMed ID: 32393973
[TBL] [Abstract][Full Text] [Related]
6. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
7. An older patient with active ulcerative colitis and coronavirus disease 2019 (COVID-19) pneumonia successfully treated with the combination of anti-TNFα therapy and azathioprine.
Yamakawa T; Ishigami K; Ohwada S; Kazama T; Hirayama D; Yoshii S; Yamano HO; Nakase H
Clin J Gastroenterol; 2023 Apr; 16(2):187-192. PubMed ID: 36417106
[TBL] [Abstract][Full Text] [Related]
8. Ulcerative Colitis in a COVID-19 Patient: A Case Report.
Aydın MF; Taşdemir H
Turk J Gastroenterol; 2021 Jun; 32(6):543-547. PubMed ID: 34405821
[TBL] [Abstract][Full Text] [Related]
9. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
Sebastian S; Walker GJ; Kennedy NA; Conley TE; Patel KV; Subramanian S; Kent AJ; Segal JP; Brookes MJ; Bhala N; Gonzalez HA; Hicks LC; Mehta SJ; Lamb CA;
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):271-281. PubMed ID: 33545083
[TBL] [Abstract][Full Text] [Related]
10. Infliximab rescue therapy in a patient with acute severe ulcerative colitis and coronavirus disease 2019 followed by Escherichia coli 0157:H7 infection: a case report.
Bekić D; Belošić Halle Ž
Croat Med J; 2021 Dec; 62(6):634-637. PubMed ID: 34981697
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
12. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.
Wu B; Tong J; Ran Z
Inflamm Bowel Dis; 2020 Jan; 26(1):24-32. PubMed ID: 30980713
[TBL] [Abstract][Full Text] [Related]
14. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel.
Din S; Kent A; Pollok RC; Meade S; Kennedy NA; Arnott I; Beattie RM; Chua F; Cooney R; Dart RJ; Galloway J; Gaya DR; Ghosh S; Griffiths M; Hancock L; Hansen R; Hart A; Lamb CA; Lees CW; Limdi JK; Lindsay JO; Patel K; Powell N; Murray CD; Probert C; Raine T; Selinger C; Sebastian S; Smith PJ; Tozer P; Ustianowski A; Younge L; Samaan MA; Irving PM
Gut; 2020 Oct; 69(10):1769-1777. PubMed ID: 32513653
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Lasa J; Olivera P
Arq Gastroenterol; 2017; 54(2):167-172. PubMed ID: 28327826
[TBL] [Abstract][Full Text] [Related]
17. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
Viganò C; Mulinacci G; Palermo A; Barisani D; Pirola L; Fichera M; Invernizzi P; Massironi S
World J Gastroenterol; 2021 Sep; 27(33):5520-5535. PubMed ID: 34588749
[TBL] [Abstract][Full Text] [Related]
18. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.
Chebli JMF; Queiroz NSF; Damião AOMC; Chebli LA; Costa MHM; Parra RS
World J Gastroenterol; 2021 Mar; 27(11):1022-1042. PubMed ID: 33776370
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission.
Viazis N; Pontas C; Manolakis A; Karampekos G; Tsoukali E; Galanopoulos M; Koustenis K; Archavlis E; Christidou A; Gazouli M; Mantzaris GJ
Acta Gastroenterol Belg; 2021; 84(3):423-428. PubMed ID: 34599566
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
